# A Study Evaluating HBM9036 Efficacy and Safety on Moderate to Severe Dry Eye

> **NCT04633213** · PHASE3 · COMPLETED · sponsor: **Harbour BioMed (Guangzhou) Co. Ltd.** · enrollment: 577 (actual)

## Conditions studied

- Dry Eye

## Interventions

- **DRUG:** HBM9036 0.25% Ophthalmic Solution
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04633213
- **Lead sponsor:** Harbour BioMed (Guangzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-25
- **Primary completion:** 2022-08-07
- **Final completion:** 2022-08-07
- **Target enrollment:** 577 (ACTUAL)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04633213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04633213, "A Study Evaluating HBM9036 Efficacy and Safety on Moderate to Severe Dry Eye". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04633213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*